First Choice Neurology

Dr. Jeffrey Gelblum

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients

Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab, the $56,000-a-year drug helps patients. There is also uncertainty about reimbursement from Medicare. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) …

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »

COVID-19: Roadmap to Reopening

First Choice Neurology is hosting a new series of Facebook Live events this month – COVID-19: Roadmap to Reopening. Jeffrey Gelblum, MD kicked off the series yesterday presenting “Re-engaging Older Loved Ones”. He talked about the coronavirus pandemic and endemic. Dr. Gelblum talks about the components of infectivity (Ro): 1. Duration – how long are …

COVID-19: Roadmap to Reopening Read More »

Am I Safe if My COVID-19 Blood Test is Antibody Positive?

On Monday, April 20, Dr. Jeffrey Gelblum will present a Facebook Live event at 12:30 (Eastern Time) to talk about COVID-19 and blood tests that are antibody positive. Dr. Gelblum will educate us about antibody tests and COVID-19. What are Antibodies? Antibodies are proteins that can stick to the surface of bacteria and viruses. They …

Am I Safe if My COVID-19 Blood Test is Antibody Positive? Read More »

Virtual Neurology Office via Telehealth

Written by Jeffrey Gelblum, MD A “Virtual Neurology Office” is a fully functional neurology office accessible online via new Telehealth technology. The physicians of First Choice Neurology have pioneered the use of Telehealth to enable patients anywhere in the world to access their neurology doctor without ever setting foot in a physical office. This is …

Virtual Neurology Office via Telehealth Read More »

BAN2401 Study to Assess New Alzheimer’s Treatment

If you or a loved one are experiencing signs of early Alzheimer’s disease, there may soon be treatment and hope on the horizon. First Choice Neurology is participating in an FDA-approved Phase III clinical trial to determine the benefit of an experimental product, BAN2401.   What is BAN2401 for Alzheimer’s? BAN2401 is a new class …

BAN2401 Study to Assess New Alzheimer’s Treatment Read More »

HAPPIN Study Seeks Patients with Idiopathic Neuropathy

First Choice Neurology is launching the HAPPIN Study (Hereditary Amyloid Polyneuropathy Prevalence in Idiopathic Neuropathy). It is the nation’s first research study of the prevalence of hereditary amyloid neuropathy. Doctors at First Choice Neurology will be evaluating a large group of patients with idiopathic neuropathy to determine if they possess a hereditary marker for amyloid …

HAPPIN Study Seeks Patients with Idiopathic Neuropathy Read More »

Familial Amyloid Polyneuropathy

What is Familial Amyloid Polyneuropathy? Familial Amyloid Polyneuropathy (FAP) is an inherited disease that causes progressive sensorimotor and autonomic nerve disorder. Peripheral nerve degeneration (polyneuropathy) begins in small fibers, resulting in sensory symptoms of numbness, burning, and tingling — typically in the feet. This progresses to larger nerve fibers, which leads to muscle weakness and …

Familial Amyloid Polyneuropathy Read More »

Translate »